| ISIN | US00162Q5936 |
|---|---|
| TER | 0.01% |
| Replication | Synthetic |
| Distribution | Accumulating |
| Launch Year | 2014 |
| AUM | $0.08 billion |
| Provider | ALPS |
| Exchange | London Exchange (UK) |
| Currency | USD |
| Country | UK |
| Type | ETF |
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Consult fund provider.
| Period | Return (%) |
|---|---|
| 1 Month | 3.99% |
| 3 Months | -12.28% |
| 6 Months | -22.44% |
| 1 Year | -7.16% |
| 3 Years | 18.94% |
| 5 Years | -30.26% |
| Since Inception | 25.38% |
Distribution: Accumulating
Volatility and risk metrics are calculated based on historical price movements.
This ETF is widely available on major European brokers like Trade Republic, Scalable, and DEGIRO.
Compare brokers →Exchange: London Exchange (UK)
Currency: USD
Is this ETF accumulating?
Yes, it reinvests dividends.